| HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis MJ McElrath, SC De Rosa, Z Moodie, S Dubey, L Kierstead, H Janes, ... The Lancet 372 (9653), 1894-1905, 2008 | 886 | 2008 |
| Effect of dengue serostatus on dengue vaccine safety and efficacy S Sridhar, A Luedtke, E Langevin, M Zhu, M Bonaparte, T Machabert, ... New England Journal of Medicine 379 (4), 327-340, 2018 | 784 | 2018 |
| mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection L Stamatatos, J Czartoski, YH Wan, LJ Homad, V Rubin, H Glantz, ... Science 372 (6549), 1413-1418, 2021 | 587 | 2021 |
| Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells KW Cohen, SL Linderman, Z Moodie, J Czartoski, L Lai, G Mantus, ... Cell Reports Medicine 2 (7), 2021 | 458 | 2021 |
| Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study GE Gray, M Allen, Z Moodie, G Churchyard, LG Bekker, M Nchabeleng, ... The Lancet infectious diseases 11 (7), 507-515, 2011 | 458 | 2011 |
| Phase 1 safety and immunogenicity evaluation of a multiclade HIV‐1 candidate vaccine delivered by a replication‐defective recombinant adenovirus vector AT Catanzaro, RA Koup, M Roederer, RT Bailer, ME Enama, Z Moodie, ... The Journal of infectious diseases 194 (12), 1638-1649, 2006 | 380 | 2006 |
| A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial JE Martin, NJ Sullivan, ME Enama, IJ Gordon, M Roederer, RA Koup, ... Clinical and vaccine immunology 13 (11), 1267-1277, 2006 | 304 | 2006 |
| Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination H Horton, EP Thomas, JA Stucky, I Frank, Z Moodie, Y Huang, YL Chiu, ... Journal of immunological methods 323 (1), 39-54, 2007 | 284 | 2007 |
| Overcoming immunity to a viral vaccine by DNA priming before vector boosting Z Yang, LS Wyatt, W Kong, Z Moodie, B Moss, GJ Nabel Journal of virology 77 (1), 799-803, 2003 | 266 | 2003 |
| Phase 1 safety and immunogenicity evaluation of a multiclade HIV‐1 DNA candidate vaccine BS Graham, RA Koup, M Roederer, RT Bailer, ME Enama, Z Moodie, ... The Journal of infectious diseases 194 (12), 1650-1660, 2006 | 257 | 2006 |
| Response definition criteria for ELISPOT assays revisited Z Moodie, L Price, C Gouttefangeas, A Mander, S Janetzki, M Löwer, ... Cancer Immunology, Immunotherapy 59, 1489-1501, 2010 | 242 | 2010 |
| Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults GE Gray, LG Bekker, F Laher, M Malahleha, M Allen, Z Moodie, ... New England Journal of Medicine 384 (12), 1089-1100, 2021 | 219 | 2021 |
| A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204) GJ Churchyard, C Morgan, E Adams, J Hural, BS Graham, Z Moodie, ... PloS one 6 (8), e21225, 2011 | 178 | 2011 |
| Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study GE Gray, Z Moodie, B Metch, PB Gilbert, LG Bekker, G Churchyard, ... The Lancet infectious diseases 14 (5), 388-396, 2014 | 164 | 2014 |
| Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines WP Kong, Y Huang, ZY Yang, BK Chakrabarti, Z Moodie, GJ Nabel Journal of virology 77 (23), 12764-12772, 2003 | 130 | 2003 |
| Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial LG Bekker, Z Moodie, N Grunenberg, F Laher, GD Tomaras, KW Cohen, ... The lancet HIV 5 (7), e366-e378, 2018 | 125 | 2018 |
| Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax® challenge in vaccinia-naïve and vaccinia-immune individuals J Parrino, LH McCurdy, BD Larkin, IJ Gordon, SE Rucker, ME Enama, ... Vaccine 25 (8), 1513-1525, 2007 | 111 | 2007 |
| Neutralizing antibody correlates analysis of tetravalent dengue vaccine efficacy trials in Asia and Latin America Z Moodie, M Juraska, Y Huang, Y Zhuang, Y Fong, LN Carpp, SG Self, ... The Journal of infectious diseases 217 (5), 742-753, 2018 | 104 | 2018 |
| Virus-Specific CD8+ T-Cell Responses Better Define HIV Disease Progression than HLA Genotype WL Dinges, J Richardt, D Friedrich, E Jalbert, Y Liu, CE Stevens, ... Journal of virology 84 (9), 4461-4468, 2010 | 79 | 2010 |
| Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials Z Moodie, Y Huang, L Gu, J Hural, SG Self Journal of immunological methods 315 (1-2), 121-132, 2006 | 76 | 2006 |